Lasa Supergeneri Q1 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- The company expects a sustainable year-on-year growth of around 20% in sales/revenue.
- There is a plan to launch two blockbuster products with strong and consistent market demand, each with a large market size (one around Rs. 2000 Crores).
- Export contribution has increased significantly to 40%, boosting revenue growth from new geographies like Russia and the Middle East.
- Expansion through new units and debottlenecking existing plants will support volume growth.
- The company emphasizes focusing on core products with low risk profiles rather than diversifying excessively.
- Growth is targeted through backward integration to improve cost efficiency, particularly in Albendazole.
- Despite seasonal factors and regulatory challenges, long-term annual growth guidance remains robust around 20%.
- Improved demand trends post-pandemic and focus on cash flow enhancement provide a positive outlook for breaking past records in upcoming years.
See what Lasa Supergeneri management said on margin guidance — free account, 30 seconds.
Fundraise plans
- LASA Supergenerics is not raising new debt; all recent capex has been funded through internal accruals (debt-free capex).
- The company is focusing on generating cash surplus on the balance sheet, aiming for around Rs. 200-300 Crores cash surplus.
- There is no mention of any immediate equity fundraising; the company prefers organic growth through project execution rather than acquiring new companies.
- Post-merger with Harishree, paid-up capital will increase from Rs. 40 Crores to Rs. 50 Crores, but this is related to the merger process and not fresh equity raising.
- Management emphasized a strategy to improve cash flow and maintain a debt-free balance sheet rather than raising new capital through debt or equity in the near term.
See what Lasa Supergeneri management said on order book — free account, 30 seconds.
Capex plans
Yes- LASA is undertaking capex primarily through internal accruals, maintaining a debt-free status for expansions.
- Capex includes adding new reactors (17-18 procured recently) for new blockbuster products with large market potential (~Rs. 2000 Crores product).
- Expansion involves new unit (Unit II) and debottlenecking existing units; full plant capacity expected to be reached in about one year.
- Backward integration efforts ongoing, especially in Albendazole production to improve cost control and competitiveness.
- Brownfield expansions planned using available land bank (50 acres, with only 5 acres currently used) and environment clearances.
- Focus is on project execution rather than acquiring new companies, aiming high ROI (~10x capex).
- Upcoming press releases will detail new product launches and capex specifics.
- Strategic aim to bring 200-300 Crores cash surplus on balance sheet through organic growth and expansion.
Track Lasa Supergeneri — get its next earnings analysis in your feed
Margin guidance
Category 3- The company expects a sustainable year-on-year growth of around 20% in revenues and PAT.
- Quarter-on-quarter growth is seasonal and impacted by regulatory issues, so annual evaluation based on PAT is recommended.
- EBITDA margins are expected to fluctuate between 20% and 25%, with current margins around 22-23%, considered sustainable barring unforeseen events.
- The company is launching two blockbuster products with a single-product market size around Rs. 2000 Crores, expected to drive growth over the next 2-3 years.
- Exports have increased to 40% of revenue, contributing significantly to margin expansion and top-line growth.
- Operating cash flows are strong, with zero finance cost and improved return on capital focus, enabling capex through internal accruals without debt.
- Overall, the outlook suggests consistent topline growth with improved profitability and EPS growth driven by product launches and operational efficiencies.
Order book
How does Lasa Supergeneri rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Lasa Supergeneri rank in Pharmaceuticals & Biotechnology?
Compare Lasa Supergeneri against every Pharmaceuticals & Biotechnology company (Q1 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Lasa Supergeneri's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma Science Ltd (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…